Hospital Pharmacy Europe is delighted to announce that NHS England’s Paul Ryan will be joining our expert speaker line-up at the Biosimilars Virtual Study Day on 4 March 2026.
The event will provide authoritative insights into clinically safe and efficient biosimilar switching, adverse event management and the practical realities of implementation across secondary, primary, paediatric and homecare settings.
The forward-looking session from Paul Ryan, lead pharmacist medicines value and access at NHS England, will focus on what 2026 holds for pharmacists as payment model changes edge closer, as well as the financial and governance benefits of biosimilar switching and overcoming potential hesitancy.
More specifically, the session will cover NHS England’s perspective on upcoming reimbursement and commissioning reforms, examine the practical impact of the ‘best-value biologic or biosimilar first’ agenda, and consider the implications for prescribing and biosimilar switching in both the hospital and homecare pathways.
Paul will also touch on the details of how new patients should be on a biosimilar within three months and the risks and opportunities for pharmacists in delivering value-based biosimilar use.
Practical strategies to optimise biosimilar switching
Following the session, attendees will be better equipped to align clinical practice with future funding models, influence local strategy, and position pharmacy as a system leader.
It’s more important than ever to effectively navigate prescribing, switching strategies and optimise pharmacist leadership in this area so if you’re involved in biologics, biosimilars, medicines governance or system transformation, this session is a must-attend.
Gain knowledge you can apply immediately in your practice, along with the insight needed to prepare for the future of value-based biologic use in the NHS, and capitalise on this valuable opportunity to secure a planned CPD learning activity for your revalidation.
So, register now for free to join the Hospital Pharmacy Europe team and biosimilars virtual study day chair Andrew Pothecary, lead pharmacist, rheumatology and biologics at Royal Cornwall Hospitals NHS Trust, at next week’s event.
